In patients having transjugular intrahepatic portosystemic shunt, rifaximin prevented overt hepatic encephalopathy
- PMID: 34224266
- DOI: 10.7326/ACPJ202107200-078
In patients having transjugular intrahepatic portosystemic shunt, rifaximin prevented overt hepatic encephalopathy
Abstract
Bureau C, Thabut D, Jezequel C, et al. The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial. Ann Intern Med. 2021;174:633-40. 33524293.
Comment on
-
The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.Ann Intern Med. 2021 May;174(5):633-640. doi: 10.7326/M20-0202. Epub 2021 Feb 2. Ann Intern Med. 2021. PMID: 33524293 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources